Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health, Inc. develops precision oncology diagnostics and data products centered on blood and tissue testing for cancer care. Company news commonly covers the Guardant360 liquid biopsy and Guardant360 Tissue franchises, Guardant Reveal for molecular residual disease monitoring, Shield colorectal cancer screening, and InfinityAI real-world data and analytics.
Recurring updates include financial results across Oncology, Screening, and Biopharma & Data revenue categories; FDA companion diagnostic approvals for Guardant360 CDx; research presentations in tumor typing, therapy selection, methylation and multiomic testing; and biopharma collaborations that use Guardant tissue and liquid biopsy assays to support targeted therapy development.
Guardant Health and AnHeart Therapeutics announced a strategic collaboration focused on developing Guardant360 CDx and Guardant360 TissueNext assays as companion diagnostics for taletrectinib, an investigational ROS1 inhibitor targeting advanced non-small cell lung cancer (NSCLC). This partnership aims to expedite regulatory approval and improve patient access to advanced diagnostic tools. Taletrectinib has received FDA Breakthrough Therapy Designation for ROS1-positive NSCLC patients. The collaboration will utilize comprehensive genomic profiling to identify suitable patients for this therapy, enhancing treatment outcomes.
Guardant Health, Inc. (Nasdaq: GH) announced a favorable recommendation from U.S. District Court Magistrate Judge Christopher J. Burke regarding Illumina's lawsuit filed on March 17, 2022. The judge recommended that nearly all of Illumina's claims be dismissed, affirming Guardant's belief in the validity of its patent ownership. This dismissal is viewed as a significant step in Guardant's mission to enhance cancer care. Guardant Health continues to advance its precision oncology platform with various proprietary tests aimed at improving patient outcomes and reducing healthcare costs.
Guardant Health (NASDAQ: GH) is set to report its financial results for the fourth quarter and full year 2022 after market close on February 23, 2023. The corresponding conference call will start at 1:30 p.m. PT (4:30 p.m. ET). Listeners can access the live webcast and subsequent archive in the Investors section of the company’s website.
Guardant Health specializes in precision oncology, providing proprietary tests and advanced analytics aimed at improving cancer treatment outcomes and reducing healthcare costs.
Guardant Health (NASDAQ: GH) has unveiled Guardant Galaxy, a suite of AI-powered analytical technologies aimed at enhancing cancer testing and drug discovery. The first application, developed in collaboration with Lunit, improves biomarker detection by over 20% for the Guardant360 TissueNext PD-L1 test in non-small cell lung cancer cases. Future applications will focus on deep learning-driven genomic and epigenomic discovery, leveraging real-world clinical data from the GuardantINFORM platform. The initiative aims to provide oncologists with precise information and to accelerate biomarker discovery.
Guardant Health (GH) announced FDA approval for its Guardant360 CDx liquid biopsy test, which identifies advanced breast cancer patients with ESR1 mutations eligible for ORSERDU™ (elacestrant) therapy, a significant breakthrough for a major unmet medical need. This marks the first new endocrine therapy innovation in over 20 years, targeting the 40% of ER+/HER2- advanced breast cancers driven by ESR1 mutations. ORSERDU, developed by Stemline Therapeutics, is designed for patients whose disease has progressed after at least one line of endocrine therapy. The approval followed the Phase III EMERALD trial, demonstrating significant progression-free survival benefits.
Guardant Health (GH) partners with The Royal Marsden NHS Foundation Trust to conduct Part C of the TRACC study, evaluating the effectiveness of the Guardant Reveal™ blood test in guiding chemotherapy decisions for stage II-III colorectal cancer patients. The trial will involve over 1,600 patients at around 40 sites in the UK, aiming to determine if patients who test negative for circulating tumor DNA (ctDNA) can avoid unnecessary chemotherapy, thus reducing associated side effects. The study's aim is to enhance patient quality of life and optimize treatment protocols while potentially saving healthcare costs.
Guardant Health (NASDAQ: GH) will present new data at the ASCO 2023 Gastrointestinal Cancers Symposium from January 19-21 in San Francisco. The company will showcase 10 poster presentations emphasizing the roles of its blood tests, Guardant360 and Guardant Reveal, along with the GuardantINFORM dataset. These findings aim to enhance the understanding of biomarkers and predict disease recurrence in gastrointestinal cancers. Notably, the presentations will cover topics such as ctDNA-based detection in colorectal cancers and treatment response assessments, highlighting the potential of liquid biopsies in personalized oncology.
Guardant Health (NASDAQ: GH) reported preliminary, unaudited results for 2022, showing a revenue increase of 20% to between $447 million and $450 million. Clinical and biopharma test volumes rose by 42% and 40%, with 124,800 and 26,000 tests respectively. For Q4 2022, revenue was projected between $124 million and $127 million, up 15%-17% year-over-year. The company ended the year with $1 billion in cash and equivalents. Analysts express optimism for continued double-digit growth in 2023.
Guardant Health, a leading precision oncology company, will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, at 3:00 p.m. PT. The management will present and engage in a Q&A session, with a live and archived webcast available on their website. Guardant Health is known for its innovative cancer testing solutions, including Guardant360® and Guardant Reveal™, aimed at improving patient outcomes and lowering healthcare costs. For more details, visit guardanthealth.com.
Guardant Health has partnered with Susan G. Komen to enhance breast cancer care. This collaboration aims to develop clinical studies focusing on high-risk early-stage breast cancer patients, utilizing Guardant Reveal™, a blood test for detecting minimal residual disease (MRD). By integrating input from patient advocates, the partnership seeks to create patient-centric research that informs treatment strategies. The initiative aligns with the goal of improving outcomes through personalized cancer monitoring and therapy.